Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat

被引:13
作者
Piechocki, MP
Pilon, SA
Kelly, C
Wei, WZ
机构
[1] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Otolaryngol, Detroit, MI 48201 USA
[3] Wayne State Univ, Dept Immunol & Microbiol, Detroit, MI 48201 USA
关键词
antigen processing and presentation; proteasome; CTL; GA repeat; ErbB-2; Her-2; Neu;
D O I
10.1006/cimm.2001.1853
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
ErbB-2 is ubiquitinated and degraded when dissociated from its membrane chaperone or bound by specific antibody. Reagents which induce such degradation have demonstrated antitumor activity and may impact ErbB-2 immunogenicity. To further understand ErbB-2 degradation and immunogenicity, a glycine-alanine repeat (GAr) or the reverse proline-alanine repeat (PAr) which protects certain proteins from proteasome degradation, was inserted after amino acid 5 (GAr5/PAr5) or 55 (GAr55/PAr55) of ErbB-2. When dissociated from the membrane with geldanamycin, E2-GAr5 and E2-PAr5 were not protected and still ubiquitinated and degraded by the proteasome, despite the presence of GAr. Insertional mutagenesis with GAr sequences at a.a. 55 of E2 enhanced proteasome degradation rendering E2-GAr55 and E2-PAr55 unstable on the membrane, but rescued in the cytosol by proteasome inhibitors. Immunization with E2-GAr induced antitumor immunity and CTL which lysed tumor cells expressing chimeric E2-GAr or wild-type E2 proteins, demonstrating efficient presentation through MHC I pathway. Improved understanding of the strong degradation signals in ErbB-2 may facilitate the development of anticancer agents or vaccines. (C) 2001 Elsevier Science.
引用
收藏
页码:138 / 149
页数:12
相关论文
共 33 条
[1]   THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
NATURE, 1986, 319 (6050) :226-230
[2]   A SINGLE AUTOPHOSPHORYLATION SITE CONFERS ONCOGENICITY TO THE NEU/ERBB-2 RECEPTOR AND ENABLES COUPLING TO THE MAP KINASE PATHWAY [J].
BENLEVY, R ;
PATERSON, HF ;
MARSHALL, CJ ;
YARDEN, Y .
EMBO JOURNAL, 1994, 13 (14) :3302-3311
[3]   Human CD8+ T cell responses to EBV EBNA1:: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing [J].
Blake, N ;
Lee, S ;
Redchenko, I ;
Thomas, W ;
Steven, N ;
Leese, A ;
Steigerwald-Mullen, P ;
Kurilla, MG ;
Frappier, L ;
Rickinson, A .
IMMUNITY, 1997, 7 (06) :791-802
[4]   The importance of exogenous antigen in priming the human CD8+ T cell response:: Lessons from the EBV nuclear antigen EBNA1 [J].
Blake, N ;
Haigh, T ;
Shaka'a, G ;
Croom-Carter, D ;
Rickinson, A .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :7078-7087
[5]   Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells [J].
Dantuma, NP ;
Lindsten, K ;
Glas, R ;
Jellne, M ;
Masucci, MG .
NATURE BIOTECHNOLOGY, 2000, 18 (05) :538-543
[6]   ANTIBODIES AGAINST A SYNTHETIC PEPTIDE IDENTIFY THE EPSTEIN-BARR VIRUS-DETERMINED NUCLEAR ANTIGEN [J].
DILLNER, J ;
STERNAS, L ;
KALLIN, B ;
ALEXANDER, H ;
EHLINHENRIKSSON, B ;
JORNVALL, H ;
KLEIN, G ;
LERNER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (15) :4652-4656
[7]  
DISIS ML, 1994, CANCER RES, V54, P16
[8]   Setting the standards: Quality control in the secretory pathway [J].
Ellgaard, L ;
Molinari, M ;
Helenius, A .
SCIENCE, 1999, 286 (5446) :1882-1888
[9]  
FENDLY BM, 1990, CANCER RES, V50, P1550
[10]  
Fisk B, 1997, CANCER RES, V57, P87